Use of Immunotherapy in Patients With Cancer During the COVID-19 Pandemic

After the first case was reported in Wuhan, China, at the end of 2019, COVID-19 reached global proportions, leading the World Health Organization to declare it a pandemic on March 11, 2020. [...]published data are conflicting; some data show serious outcomes in patients receiving immunotherapy, whil...

Full description

Saved in:
Bibliographic Details
Published inOncology (Williston Park, N.Y.) no. 3409; pp. 370 - 373
Main Authors Soares, Andrey, Schutz, Fabio, Bastos, Diogo, Jardim, Denis, Monteiro, Fernando
Format Journal Article
LanguageEnglish
Published Monmouth Junction MultiMedia Healthcare Inc 15.09.2020
Subjects
Antibodies
Asymptomatic
Cancer therapies
Coronaviruses
COVID-19
COVID-19 diagnostic tests
Cytokines
Disease transmission
Immunotherapy
Infections
Lymphatic system
Medical imaging
Mortality
Pandemics
Patients
Radiation therapy
Severe acute respiratory syndrome coronavirus 2
Viral infections
Online AccessGet full text

Cover

More Information
Summary:After the first case was reported in Wuhan, China, at the end of 2019, COVID-19 reached global proportions, leading the World Health Organization to declare it a pandemic on March 11, 2020. [...]published data are conflicting; some data show serious outcomes in patients receiving immunotherapy, while others do not.6-12 Considering the magnitude of the pandemic, several expert-opinion guidelines have emerged, aiming to minimize both the risk of infection and complications related to COVID-19. [...]only observational studies have raised the possibility of the protective effect of IMT, and further data are required to confirm this hypothesis and use it to guide the management of patients with cancer. Yet it is known that in severe cases of pneumonitis, the host experiences exacerbated inflammation, and in these cases, the use of IMT could enhance the inflammatory response. [...]the second quandary oncologists face is the challenge to correctly diagnosis SARS-CoV-2 infection or IMT-induced pneumonitis.4,6,11 Another important consideration is controlling immune-related AEs in patients who need long-term immunosuppression therapy.
ISSN:0890-9091
DOI:10.46883/ONC.2020.3409.0370